Cessatech is a pivotal-stage paediatric biotech company developing first-in-class specialty hospital medicines for children, focused on high-impact unmet needs in acute and emergency care. The company focuses on specialty products designed for use in clinical settings and advances its programs through a partnership-based development model. Founded in 2020, Cessatech is headquartered in Denmark and led by a team with experience across drug development and commercialization.
CEO
Chairperson of the Board
Board
| Name | Capital % | Votes % | Date |
|---|---|---|---|
| Jes Trygved | 5,32 | 5,32 | 2024-12-31 |
| Steen Winther Henneberg | 3,63 | 3,63 | 2022-12-29 |
| Bettina Nygaard Nielsen | 3,63 | 3,63 | 2022-12-29 |
| Henriksen Group Aps | 2,80 | 2,80 | 2022-12-29 |
| Martin Olin | 2,05 | 2,05 | 2024-12-31 |
| Adam Steensberg | 1,20 | 1,20 | 2023-12-31 |
| Rachel Curtis Gravesen | 1,17 | 1,17 | 2024-12-31 |
| Charlotte Videbaek | 1,00 | 1,00 | 2024-12-31 |
| Anders Dyhr Dombernowsky-Tof | 0,29 | 0,29 | 2024-12-31 |
| Peter Birk | 0,07 | 0,07 | 2023-12-31 |
2026-11-26 Interim Report 2026-Q3
